
## **Supplemental Digital Content 2**

## FIGURE: Study Design



CAZ-AVI Dosing by Age Cohort and Renal Status			
Cohort	Age range	CrCL 50 mL/min	CrCL 30 to <50 mL/min
Cohort 1	12 years to <18 years	2000 mg CAZ/500 mg AVI for patients ≥40 kg or 50 mg/kg CAZ/12.5 mg/kg AVI for patients <40 kg	1000 mg CAZ/250 mg AVI for patients ≥40 kg or 25 mg/kg CAZ/6.25 mg/kg AVI for patients <40 kg
Cohort 2	6 years to <12 years		
Cohort 3	2 years to <6 years	50 mg/kg CAZ/12.5 mg/kg AVI	25 mg/kg CAZ/6.25 mg/kg AVI
Cohort 4	6 months to <2 years	50 mg/kg CAZ/12.5 mg/kg AVI	25 mg/kg CAZ/6.25 mg/kg AVI
	3 months to <6 months	40 mg/kg CAZ/10 mg/kg AVI	20 mg/kg CAZ/5 mg/kg AVI

†Optional switch to oral therapy (amoxicillin/clavulanic acid, ciprofloxacin plus metronidazole or pathogen culture-based therapy) permitted on or after study Day 4 (ie, after 3 full days/9 doses of IV study drug). ‡The maximum dose of meropenem for patients weighing >50 kg was 1 g every 8 hours. §Or infusion duration as per local guidelines. PVisit carried out within 24 hours of completion of last infusion or within 48 hours after the last dose of oral switch therapy.

CAZ-AVI, ceftazidime-avibactam; cIAI, complicated intra-abdominal infection; IV, intravenous; MTZ, metronidazole.